Table 5 Univariate analyses and Multivariate analyses for overall survival in patients with endometrial carcinoma about clinicopathological features and mesothelin, CA125 expressions
From: Significance of mesothelin and CA125 expression in endometrial carcinoma: a retrospective analysis
Variables | Â | Univariate analysis | Multivariate analysis for mesothelin expression | Multivariate analysis for co-expression of mesothelin and CA125 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
HR | (95% CI) | p-value | HR | (95% CI) | p-value | HR | (95% CI) | p-value | ||
Age | ≥ 60 vs. <  60 | 2.01 | (1.23–3.35) | < 0.01 | 1.56 | (0.91–2.70) | 0.10 | 1.55 | (0.91–2.70) | 0.10 |
Histological type | Grade 2 endometrioid carcinoma vs. Grade 1 endometrioid carcinoma | 2.92 | (1.36–6.39) | < 0.01 | 1.46 | (0.63–3.42) | 0.36 | 1.47 | (0.63–3.45) | 0.36 |
|  | Grade 3 endometrioid carcinoma vs. Grade 1 endometrioid carcinoma | 5.30 | (2.46–11.6) | < 0.01 | 3.68 | (1.58–8.78) | < 0.01 | 3.70 | (1.58–8.82) | < 0.01 |
|  | Other carcinomas vs. Grade 1 endometrioid carcinoma | 8.22 | (4.22–17.0) | < 0.01 | 2.97 | (1.34–6.87) | < 0.01 | 2.99 | (1.35–6.91) | < 0.01 |
FIGO stage | III.IV vs. I.II | 7.05 | (4.35–11.6) | < 0.01 | 1.62 | (0.64–3.98) | 0.29 | 1.61 | (0.64–3.95) | 0.30 |
Depth of myometrial invasion | ≥1/2 vs. < 1/2 | 3.59 | (2.22–5.92) | < 0.01 | 1.47 | (0.78–2.80) | 0.23 | 1.45 | (0.77–2.78) | 0.24 |
Lymphovascular invasion | Yes vs. no | 3.96 | (2.37–6.87) | < 0.01 | 2.47 | (1.25–4.90) | < 0.01 | 2.46 | (1.25–4.89) | < 0.01 |
Cervical invasion | Yes vs. no | 2.11 | (1.25–3.46) | < 0.01 | 1.34 | (0.73–2.40) | 0.33 | 1.34 | (0.73–2.41) | 0.33 |
Ovarian metastasis | Yes vs. no | 10.3 | (5.95–17.3) | < 0.01 | 1.75 | (0.86–3.57) | 0.12 | 1.75 | (0.86–3.57) | 0.12 |
Lymph node metastasis | Yes vs. no | 4.50 | (2.47–8.04) | < 0.01 | 1.15 | (0.52–2.62) | 0.72 | 1.15 | (0.51–2.61) | 0.72 |
|  | Yes vs. unevaluated | 1.09 | (0.58–2.01) | 0.77 | 0.92 | (0.43–1.97) | 0.84 | 0.92 | (0.43–1.97) | 0.84 |
|  | Unevaluated vs. no | 4.11 | (2.34–7.15) | < 0.01 | 1.24 | (0.62–2.44) | 0.52 | 1.24 | (0.62–2.43) | 0.53 |
Distant metastasis | Yes vs. no | 13.8 | (8.14–22.8) | < 0.01 | 5.47 | (2.45–12.4) | < 0.01 | 5.45 | (2.44–12.4) | < 0.01 |
Peritoneal cytology | Positive vs. negative | 5.18 | (3.20–8.36) | < 0.01 | 1.93 | (1.01–3.66) | 0.046 | 1.92 | (1.00–3.65) | 0.047 |
Adjuvant therapy | Yes vs. no | 2.00 | (1.20–3.43) | < 0.01 | 0.26 | (0.12–0.54) | < 0.01 | 0.26 | (0.12–0.54) | < 0.01 |
Mesothelin expression | Yes vs. no | 3.14 | (1.95–5.13) | < 0.01 | 2.18 | (1.31–3.71) | < 0.01 |  |  |  |
CA125 expression | Yes vs. no | 1.39 | (0.79–2.60) | 0.25 |  |  |  |  |  |  |
Co-expression of mesothelin and CA125 | Yes vs. no | 3.26 | (2.03–5.33) | < 0.01 |  |  |  | 2.22 | (1.33–3.77) | < 0.01 |